Tirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension (TREAT-IIH)
Tirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension: A Randomized, Double-Masked, Placebo-Controlled Phase 2 Trial of Adjunctive Tirzepatide
The goal of this clinical trial is to learn if tirzepatide, a dual GIP/GLP-1 receptor agonist, helps to treat idiopathic intracranial hypertension (IIH) when added to acetazolamide, which is the standard medical therapy for IIH. The main questions it aims to answer are:
- Does tirzepatide lower the mean daily acetazolamide dose at 12 months?
- Does tirzepatide add-on therapy improve the likelihood of remission of IIH, improve weight loss, reduce cumulative acetazolamide exposure, improve ophthalmic outcome measures, improve normalization of intracranial hypertension as measured by lumbar puncture (LP) opening pressure, improve headache and quality of life measures and, improve MRI findings of intracranial hypertension?
Investigators will compare tirzepatide to a placebo/sham injection in patients who are treated with a predefined dosing schedule of acetazolamide that adjusts based upon the response of papilledema and other IIH symptoms such as headache.
In addition to receiving treatment with acetazolamide, participants will:
- Receive weekly tirzepatide injections or a placebo/sham injection for 12 months, followed by 12 months of open-label observation.
- Attend clinic visits at enrollment and months 1, 2, 3, 5, 7, 10, and 12 for neuro-ophthalmic examination and testing.
- During other months meet with investigator or research assistant by phone for symptom documentation and medication adjustment.
- Keep a record of any significant of days with headache for more than three hours or when a medication was taken for acute treatment of headache.
調査の概要
詳細な説明
Background. Acetazolamide is the current standard medical therapy for IIH and acts through inhibiting CSF production by the choroid plexus epithelium. The IIH Treatment Trial showed that acetazolamide improves visual field mean deviation, papilledema, and weight loss versus placebo, but the absolute effects were modest, headache was not significantly improved, and tolerability of acetazolamide remains a limitation. Tirzepatide and other GLP-1 agonists have potential benefit in IIH since they are effective for weight loss, and IIH can be put into remission with roughly 25% weight loss. Direct lowering of ICP by a mechanism similar to acetazolamide was also demonstrated for exenatide, another GLP-1 agonist. It is unclear if this ability extends to other members of the GLP-1 agonist class, but it is an appealing possibility.
Design. This is a single-center, randomized, double-masked, placebo-controlled, parallel-group phase 2 trial, reported per CONSORT 2025. Randomization is 1:1, administered by the BWH Research Pharmacy, stratified by (a) papilledema grade/visual loss severity and (b) BMI category, using permuted blocks of varying size. Participants, treating clinicians, outcome assessors, and analysts are masked; only unblinded pharmacy staff know allocation.
Intervention. All participants receive extended-release acetazolamide starting at 500 mg twice daily (or 1,000 mg twice daily for Frisén grade 3 papilledema or PMD worse than -7 dB), and up-titrated to a maximum of 4 g/day. Acetazolamide dose is titrated at study visits by predefined rules based on perimetric mean deviation, papilledema (Frisén grade, OCT pRNFL), and a 14-day headache score. Participants also self-inject weekly tirzepatide or matching placebo starting at 2.5 mg one week after acetazolamide initiation, increasing monthly (5, 7.5, 10, 12.5 mg) to a maximum of 15 mg weekly as tolerated. All participants receive standardized nutrition and exercise guidance.
Visits. Screening/baseline, then visits at months 1, 2, 3, 5, 7, 10, and 12, with telephone or video contacts at months 4, 6, 8, 9, and 11. Assessments include visual acuity, automated perimetry (HVF 24-2 SITA Standard), OCT (Cirrus; Spectralis at baseline and 12 months), OCT angiography, fundus photography, weight and abdominal circumference, headache/quality-of-life/sleep questionnaires, lumbar puncture at month 12, and DXA and MRI at baseline and 12 months. After month 12, participants are followed open-label through month 24.
Primary endpoint is mean daily acetazolamide dose at the 12-month visit in participants with baseline BMI ≥27.0.
Statistics. Sample size is based on detecting a 375 mg/day difference (SD 450 mg, two-sided alpha 0.05, 80% power), requiring about 47 completers, inflated for 30% loss to follow-up. The primary analysis is a mixed linear model adjusted for stratification factors with a random site intercept. One interim analysis is planned using a group-sequential design (Lan-DeMets O'Brien-Fleming alpha spending) with a one-time promising-zone sample size adaptation.
Safety. Adverse events are graded with CTCAE v6.0. Medical and statistical monitors review safety data. Predefined criteria govern withdrawal and treatment failure.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Eleonore Kugener, MS
- 電話番号:617-525-3610
- メール:IIH-TRI@mgb.org
研究場所
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02446
- Brigham and Women's Hospital
-
副調査官:
- Marc Bouffard, MD
-
コンタクト:
- Eleonore Kugener
- 電話番号:617-525-3610
- メール:IIH-TRI@mgb.org
-
コンタクト:
- Robert Mallery, MD
- 電話番号:617-525-3610
- メール:IIH_TRI@mgb.org
-
主任研究者:
- Robert Mallery, MD
-
副調査官:
- Bart Chwalisz, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
IIH with papilledema, adapted from the 2013 diagnostic criteria and the modified Dandy criteria used in the IIH Treatment Trial:
(i) Papilledema confirmed by a neuro-ophthalmologist (ii) Lumbar puncture opening pressure >25 cm CSF within 6 weeks of enrollment with normal CSF constituents; if opening pressure is 20-25 cm CSF, at least one of: venous pulsatile tinnitus, sixth cranial nerve palsy, Frisén grade ≥2 papilledema with pseudopapilledema excluded in at least one eye, or bilateral transverse venous sinus stenosis (iii) MRI and MRV of the brain showing no cause of secondary intracranial hypertension (e.g., tumor, hydrocephalus, venous sinus thrombosis)
-
BMI ≥25
-
Able to provide informed consent
Exclusion Criteria:
- Treatment for IIH for more than 30 days in the prior year with any agent (acetazolamide, topiramate, furosemide, zonisamide, GLP-1 or dual GLP-1/GIP agonist); if on acetazolamide in the prior month, dose must not have exceeded 1 g/day
- IIH relapse at prescreen/screen
- Prior intracranial shunting, venous sinus stenting, or optic nerve sheath fenestration
- Bariatric surgery within the past year
- New cranial nerve dysfunction other than papilledema and sixth nerve palsy
- Major CT/MRI abnormalities suggesting secondary intracranial hypertension or alternate diagnosis (e.g., hydrocephalus, Chiari malformation, dural AV fistula, venous sinus thrombus, retrobulbar optic nerve enhancement suggesting optic neuritis)
- History of optic neuritis, multiple sclerosis, MOG antibody disease, neuromyelitis optica spectrum disorder, acute disseminated encephalomyelitis, or seropositivity for MOG or aquaporin-4 antibodies
- Exposure for >7 days within 2 months of symptom onset to an oral drug, substance, or disorder potentially affecting ICP (e.g., vitamin A derivatives, tetracyclines, growth hormone, lithium, corticosteroids)
- CSF leak confirmed by beta-2 transferrin within 1 month of enrollment
- Media opacity precluding adequate OCT signal strength and Frisén grading
- Unreliable automated perimetry (≥30% fixation losses, ≥20% false positives or negatives) at screening
- PMD of -15 dB or worse on reliable perimetry
- Comorbid condition requiring diuretics, systemic steroids, or other ICP-lowering agents including topiramate or zonisamide (nasal, inhaled, or topical steroids permitted)
- Intraocular pressure currently >28 mmHg or >30 mmHg at any time in the past
- Refractive error greater than ±8.00 sphere or ±3.00 cylinder in either eye if associated with anatomic abnormalities that could cause visual loss
- Optic disc drusen on fundus examination or OCT
- Other disorders causing visual loss except refractive error and amblyopia
- Lab abnormalities or conditions contraindicating acetazolamide (severe anemia, leukopenia, thrombocytopenia, renal failure, hepatic disease, calcium phosphate or calcium oxalate nephrolithiasis)
- Lab abnormalities or conditions contraindicating GLP-1/GIP agonist use, including type 1 diabetes, diabetic retinopathy, diabetes managed with insulin or a secretagogue, current hypoglycemia, gallbladder disease, pancreatitis, or personal or family history of medullary thyroid cancer
- Pregnancy, or unwillingness of participants of childbearing potential to use two methods of birth control, including a non-pharmacologic barrier method, during the study and for 1 month after
- Breastfeeding, unless willing to stop by the baseline visit
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Acetazolamide + Tirzepatide
Extended-release acetazolamide titrated per protocol (up to 4 g/day) plus weekly subcutaneous tirzepatide starting 2.5 mg and escalated monthly as tolerated to a maximum of 15 mg weekly, for 12 months; standard nutrition and exercise counseling. |
Weekly subcutaneous self-injection via autoinjector, starting 1 week after acetazolamide initiation at 2.5 mg and increasing every month to 5, 7.5, 10, 12.5, and 15 mg weekly as tolerated. Down-titration by one step and discontinuation at 2.5 mg are allowed for intolerance. Other names: Mounjaro; Zepbound. Extended-release capsules, starting at 500 mg twice daily (or 1,000 mg twice daily for Frisén grade 3 papilledema or PMD worse than -7 dB), titrated at study visits in 500 mg steps by predefined rules, maximum 4 g/day. |
|
プラセボコンパレーター:Acetazolamide + Placebo
Extended-release acetazolamide titrated per protocol (up to 4 g/day) plus weekly subcutaneous placebo injection on the same escalation schedule, for 12 months; standard nutrition and exercise counseling. |
Extended-release capsules, starting at 500 mg twice daily (or 1,000 mg twice daily for Frisén grade 3 papilledema or PMD worse than -7 dB), titrated at study visits in 500 mg steps by predefined rules, maximum 4 g/day. Weekly subcutaneous placebo injection matched to tirzepatide in appearance and delivery device, with the same dose-escalation schedule. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Mean daily acetazolamide dose at 12 months
時間枠:12 months
|
Mean daily acetazolamide dose (mg/day) at 12 months in participants with baseline BMI ≥27.0 |
12 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cumulative acetazolamide dose
時間枠:Baseline to 12 months
|
Area under the curve (cumulative dose) of acetazolamide over the study |
Baseline to 12 months
|
|
Between-group comparison of acetazolamide dose at each study visit
時間枠:Months 1, 2, 3, 5, 7, 10, 12
|
Months 1, 2, 3, 5, 7, 10, 12
|
|
|
Time to initiation of acetazolamide down-titration (days)
時間枠:Baseline to 12 months
|
Baseline to 12 months
|
|
|
Remission rate (off acetazolamide)
時間枠:Baseline to 15 months
|
Proportion of participants off acetazolamide (remission) at 12 months and sustained through the subsequent visit. |
Baseline to 15 months
|
|
Best-corrected visual acuity
時間枠:Baseline to 12 months
|
Change in best-corrected visual acuity (ETDRS, logMAR) in each eye. ≥0.3 logMAR (15-letter) change considered significant difference. |
Baseline to 12 months
|
|
Visual field perimetric mean deviation
時間枠:Baseline to 12 months
|
Change in perimetric mean deviation (HVF 24-2 SITA Standard) |
Baseline to 12 months
|
|
Papilledema Frisén grade
時間枠:Baseline to 12 months
|
Change in Frisén papilledema grade from fundus photographs (masked grader), and mean grade at each visit. |
Baseline to 12 months
|
|
Peripapillary retinal nerve fiber layer (pRNFL) thickness
時間枠:Baseline to 12 months
|
Change in mean pRNFL thickness (microns) measured using optical coherence tomography (Cirrus device) |
Baseline to 12 months
|
|
Combined ganglion cell-inner plexiform layer (GCIPL) thickness
時間枠:Baseline to 12 months
|
Change in macular ganglion cell-inner plexiform layer (GCIPL) thickness (Cirrus, microns) measured using optical coherence tomography. |
Baseline to 12 months
|
|
Peripapillary capillary density on optical coherence tomography angiography (OCT-A)
時間枠:Baseline to 12 months
|
Change in peripapillary capillary density on OCT-A (Cirrus) |
Baseline to 12 months
|
|
Change in lumbar puncture opening pressure
時間枠:Baseline to 12 months
|
LP opening pressure measured in cm cerebrospinal fluid (CSF) |
Baseline to 12 months
|
|
Proportion of patients with new spontaneous cerebrospinal fluid leak
時間枠:Baseline to 12 months
|
Baseline to 12 months
|
|
|
Composite National Eye Institute Visual Function Questionnaire 25 (VFQ-25) plus 10-item neuro-ophthalmology supplement score
時間枠:Baseline to 12 months
|
Measure of vision-related quality of life and self-reported health status on a scale of 0-100. A higher score indicates better quality of life. |
Baseline to 12 months
|
|
Migraine disability assessment test (MIDAS)
時間枠:Baseline, months 3, 7, 12
|
5-item questionnaire measuring headache-related disability over a 3 month period. Score is the sum of days from individual questions. Higher scores signify greater headache disability. Score ranges from 0-270. |
Baseline, months 3, 7, 12
|
|
Headache impact test (HIT-6)
時間枠:Baseline, months 3, 7, 12
|
6 item questionnaire measuring how headaches affect daily life, work and social activities. Score ranges from 36 (no impact) to 78 (severe impact). |
Baseline, months 3, 7, 12
|
|
14-day headache score
時間枠:Baseline, months 1-12
|
Count of days with headache lasting more than 4 hours or requiring acute medical treatment within the prior 14 days. |
Baseline, months 1-12
|
|
Time to symptom control
時間枠:Baseline to 12 months
|
Time (days) to symptom control (<4 symptom days/month of headache, pulsatile tinnitus, or transient visual obscuration). |
Baseline to 12 months
|
|
Proportion with symptom control
時間枠:Baseline to 12 months
|
Proportion of patients with symptom control (<4 days/month of headache, pulsatile tinnitus, or transient visual obscuration) |
Baseline to 12 months
|
|
Brain fog scale score
時間枠:Baseline to months 3, 7, 12
|
23 item questionnaire with total score ranging from 0 to 92. Higher scores indicate increased levels of brain fog. |
Baseline to months 3, 7, 12
|
|
Percent reduction in body weight
時間枠:Baseline to 12 months
|
Percent reduction in body weight. Positive value represents weight loss and negative value represents weight gain. |
Baseline to 12 months
|
|
Body Mass Index (BMI)
時間枠:Baseline to 12 months
|
Change in BMI measured in kg/m2. Positive value represents an increase in BMI and a negative value represents a decrease in BMI. |
Baseline to 12 months
|
|
Abdominal circumference
時間枠:Baseline to 12 months
|
Change in abdominal circumference (cm). Positive value represents increase in circumference, and negative value represents a decrease in circumference. |
Baseline to 12 months
|
|
Body fat mass
時間枠:Baseline to 12 months
|
Change in dual-energy x-ray absorptiometry (DXA) measure of body fat mass (kg). Positive value represents an increase in body fat mass, and negative value represents a reduction in body fat mass. |
Baseline to 12 months
|
|
Percent body fat
時間枠:Baseline to 12 months.
|
Change in dual-energy x-ray absorptiometry (DXA) measures of percent body fat. Positive value represents an increase in percent body fat, and negative value represents a reduction in percent body fat. |
Baseline to 12 months.
|
|
Android/gynoid ratio
時間枠:Baseline to 12 months
|
Dual-energy x-ray absorptiometry (DXA) measure of android/gynoid ratio change. A/G ratio is the percentage or mass of android (abdominal) fat divided by the gynoid (hip/thigh) fat. A higher ratio (>1.0) indicates more weight is carried in the midsection. A lower ratio (<1.0) indicates more weight is carried in the hips and thighs. Increase in A/G ratio indicates an increase in abdominal/visceral fat relative to hip/thigh fat, while a decrease in A/G ratio indicates a reduction in abdominal/visceral fat relative to hip/thigh fat. |
Baseline to 12 months
|
|
Bone mineral density
時間枠:Baseline and 12 months.
|
Change in dual-energy x-ray absorptiometry (DXA) measure of bone mineral density (g/cm2). Positive value represents an increase in bone mineral density, and negative value represents reduction in bone mineral density. |
Baseline and 12 months.
|
|
Structural magnetic resonance imaging (MRI) features of intracranial hypertension
時間枠:Baseline to 12 months
|
Change in the number of structural MRI features of intracranial hypertension (partially empty sella, optic nerve sheath distention, posterior globe flattening, and presence of transverse venous sinus stenosis). Score ranges from -4 to 4. Negative score indicates resolution of findings, and a positive score indicates development of additional findings. |
Baseline to 12 months
|
|
Pituitary gland height
時間枠:Baseline to 12 months
|
Maximum pituitary gland height (mm) measured orthogonal to the sellar floor on mid-sagittal T1 weighted MRI sequence. |
Baseline to 12 months
|
|
Optic nerve sheath diameter (mean)
時間枠:Baseline and 12 months
|
Maximum diameter of the optic nerve sheath as measured on axial T2 weighted MRI within the orbit, averaged between right and left |
Baseline and 12 months
|
|
Combined conduit score (CCS)
時間枠:Baseline to 12 months
|
Using 3D T1-weighted MRI and MR venogram time-of-flight sequences, each transverse-sigmoid sinus conduit (right and left) is evaluated between the torcula and distal sigmoid sinus. The degree of narrowing on each side is assigned a value: 0 - aplastic or flow gap; 1 - hypoplastic or narrowed to <25% expected diameter; 2 - narrowed to 25-50% expected diameter; 3 - narrowed to 50-75% expected diameter; 4 - narrowed to 75-100% expected diameter). The CCS is the sum of the scores of the right and left side and ranges from 0 to 8. From Farb et al. 2003. |
Baseline to 12 months
|
|
Diffusion tensor imaging along the perivascular space (DTI-ALPS) index
時間枠:Baseline to 12 months.
|
Change in ALPS index. It is calculated as a ratio of water diffusivity values measured along different axes in specific white matter regions near the lateral ventricles to isolate perivascular diffusivity. ALPS indices are unitless. An increase in ALPS index represents an increase in extracellular/glymphatic fluid transit. |
Baseline to 12 months.
|
|
Epworth Sleepiness Scale (ESS)
時間枠:Baseline to 12 months
|
Change in ESS. Score ranges from 0 to 24. Increase in ESS indicates worsened symptoms related to obstructive sleep apnea. |
Baseline to 12 months
|
|
STOP-Bang score (S-Snoring; T-Tired; O-Observed; P-Pressure; B-BMI; A-Age; N-Neck; G-Gender)
時間枠:Baseline to 12 months
|
Change in STOP-Bang score. Score ranges from 0 to 8. Increase in STOP-Bang indicates worsened symptoms related to obstructive sleep apnea (OSA). |
Baseline to 12 months
|
|
Apnea-hypopnea index (AHI)
時間枠:Baseline to 12 months.
|
Change in apnea-hypopnea index (AHI) in patients with obstructive sleep apnea (OSA) who also complete a follow up sleep study at 12 months. AHI are the number of breathing disturbances/hour during sleep. An increase in AHI indicates worsening of sleep disorder breathing/OSA, while a decrease in AHI indicates improvement. |
Baseline to 12 months.
|
|
Adverse Events
時間枠:Baseline to 24 months
|
Number of participants with adverse events (AE) (CTCAE v6.0) |
Baseline to 24 months
|
|
Serious Adverse Events
時間枠:Baseline to 24 months
|
Number of participants with severe adverse events |
Baseline to 24 months
|
|
Treatment-related withdrawals
時間枠:Baseline to 12 months
|
Number of participants with treatment-related withdrawals |
Baseline to 12 months
|
|
Treatment failures
時間枠:Baseline to 12 months
|
Number of patients with treatment failures |
Baseline to 12 months
|
協力者と研究者
捜査官
- 主任研究者:Robert Mallery, MD、Massachusetts General Hospital
出版物と役立つリンク
一般刊行物
- Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013 Sep 24;81(13):1159-65. doi: 10.1212/WNL.0b013e3182a55f17. Epub 2013 Aug 21.
- Farb RI, Vanek I, Scott JN, Mikulis DJ, Willinsky RA, Tomlinson G, terBrugge KG. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology. 2003 May 13;60(9):1418-24. doi: 10.1212/01.wnl.0000066683.34093.e2.
- Hopewell S, Chan AW, Collins GS, Hrobjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomized trials. Nat Med. 2025 Jun;31(6):1776-1783. doi: 10.1038/s41591-025-03635-5. Epub 2025 Apr 15.
- Sioutas GS, Mualem W, Reavey-Cantwell J, Rivet DJ 2nd. GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension. JAMA Neurol. 2025 Sep 1;82(9):887-894. doi: 10.1001/jamaneurol.2025.2020.
- Kravetz L, Leeman S, Regev T, Walter E, Horev A, Ofri M, Kerman T, Watted M, Buklan K, Hin W, Elobra Y, Tsumi E. The effect of glucagon-like peptide-1 agonists on ocular parameters in idiopathic intracranial hypertension patients: a retrospective study. Eye (Lond). 2025 Jul;39(10):2090-2095. doi: 10.1038/s41433-025-03807-0. Epub 2025 Apr 29.
- Friedman DI, Quiros PA, Subramanian PS, Mejico LJ, Gao S, McDermott M, Wall M; and the NORDIC IIHTT Study Group. Headache in Idiopathic Intracranial Hypertension: Findings From the Idiopathic Intracranial Hypertension Treatment Trial. Headache. 2017 Sep;57(8):1195-1205. doi: 10.1111/head.13153. Epub 2017 Jul 28.
- Krajnc N, Itariu B, Macher S, Marik W, Harreiter J, Michl M, Novak K, Wober C, Pemp B, Bsteh G. Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension. J Headache Pain. 2023 Jul 18;24(1):89. doi: 10.1186/s10194-023-01631-z.
- Mitchell JL, Lyons HS, Walker JK, Yiangou A, Grech O, Alimajstorovic Z, Greig NH, Li Y, Tsermoulas G, Brock K, Mollan SP, Sinclair AJ. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023 May 2;146(5):1821-1830. doi: 10.1093/brain/awad003.
- NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee; Wall M, McDermott MP, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, Katz DM, Keltner JL, Schron EB, Kupersmith MJ. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA. 2014 Apr 23-30;311(16):1641-51. doi: 10.1001/jama.2014.3312.
- Mollan SP, Mitchell JL, Ottridge RS, Aguiar M, Yiangou A, Alimajstorovic Z, Cartwright DM, Grech O, Lavery GG, Westgate CSJ, Vijay V, Scotton W, Wakerley BR, Matthews TD, Ansons A, Hickman SJ, Benzimra J, Rick C, Singhal R, Tahrani AA, Brock K, Frew E, Sinclair AJ. Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension: A Randomized Clinical Trial. JAMA Neurol. 2021 Jun 1;78(6):678-686. doi: 10.1001/jamaneurol.2021.0659.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- 2026P002645
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
We did not seek MGB IRB approval for data sharing outside of Mass General Brigham.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。